Gregg Gilbert
Stock Analyst at Truist Securities
(2.28)
# 2,549
Out of 5,182 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $17.46 | -2.63% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $35.47 | +4.31% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $58.62 | +43.30% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $939.47 | -44.12% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $4.27 | +204.45% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $10.58 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $121.42 | -23.41% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $24.21 | +98.27% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.68 | +1,447.62% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.50 | +29,900.00% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $10.86 | +618.23% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $117.86 | -33.82% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $30.82 | -41.60% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $204.92 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $194.20 | -9.89% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $207.94 | -68.26% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $17.46
Upside: -2.63%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $35.47
Upside: +4.31%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $58.62
Upside: +43.30%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $939.47
Upside: -44.12%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $4.27
Upside: +204.45%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $10.58
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $121.42
Upside: -23.41%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $24.21
Upside: +98.27%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.68
Upside: +1,447.62%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.50
Upside: +29,900.00%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $10.86
Upside: +618.23%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $117.86
Upside: -33.82%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $30.82
Upside: -41.60%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $204.92
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $194.20
Upside: -9.89%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $207.94
Upside: -68.26%